In a report released yesterday, Martin Auster from Credit Suisse maintained a Hold rating on Ultragenyx (RARE), with a price target of $59. The company’s shares closed yesterday at $54.34.
According to TipRanks.com, Auster is a 1-star analyst with an average return of -5.5% and a 30.0% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings Inc, Alexion Pharmaceuticals, and Solid Biosciences Llc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx with a $70 average price target, a 28.8% upside from current levels. In a report issued on October 29, Morgan Stanley also maintained a Hold rating on the stock with a $70 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $90.98 and a one-year low of $41.67. Currently, Ultragenyx has an average volume of 530K.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. Last month, Shalini Sharp, the CFO & EVP of RARE bought 12,000 shares for a total of $9,720.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
